Baseline Response Rates Inform Immunotherapy Sequencing in NSCLC
Investigators were seeking clarification on optimal sequencing of the immune checkpoint inhibitor atezolizumab following treatment failure and disease progression after receipt of nivolumab and pembrolizumab.